Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. STKE, 10 April 2007
Vol. 2007, Issue 381, p. pe14
[DOI: 10.1126/stke.3812007pe14]
PERSPECTIVES
Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?
James G. Pan1* and
Tak W. Mak2*
1Campbell Family Institute for Breast Cancer Research, University Health Network TMDT East Tower, MaRs Centre, 101 College Street, 5-705, Toronto, ON M5G 1L7, Canada. 2Campbell Family Institute for Breast Cancer Research, University Health Network and Departments of Medical Biophysics and Immunology, University of Toronto, 620 University Avenue, Suite 706, Toronto, ON, M5G 2C1, Canada.
Abstract:
As a result of a spectrum of mitochondrial defects, tumor cells often preferentially use glycolysis to generate adenosine triphosphate (ATP), even in the presence of oxygen, a phenomenon known as aerobic glycolysis, or the "Warburg effect." Dichloroacetate (DCA) is an inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase (PDH), a gatekeeping enzyme for the entry of pyruvate into the mitochondrial tricarboxylic acid (TCA) cycle. In mice, DCA treatment appears to reactivate mitochondrial respiration in tumor cells, induces their selective killing, and suppresses cancer growth. These observations provide intriguing insights into the plasticity of tumor metabolism that may offer new opportunities for therapeutic intervention.
*To whom correspondence should be addressed. E-mail: tmak{at}uhnresearch.ca (T.W.M.); jpan{at}uhnres.utoronto.ca (J.G.P.)
Citation: J. G. Pan, T. W. Mak, Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? Sci. STKE2007, pe14 (2007).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
L. Bryan Ray (5 January 2010) Sci. Signal.3 (103), ec5.
[DOI: 10.1126/scisignal.3103ec5] |Abstract »
PODCASTS
Paul S. Mischel and Annalisa M. VanHook (15 December 2009) Sci. Signal.2 (101), pc23.
[DOI: 10.1126/scisignal.2101pc23] |Abstract »|Full Text »|Podcast »
RESEARCH
Taro Hitosugi, Sumin Kang, Matthew G. Vander Heiden, Tae-Wook Chung, Shannon Elf, Katherine Lythgoe, Shaozhong Dong, Sagar Lonial, Xu Wang, Georgia Z. Chen, Jianxin Xie, Ting-Lei Gu, Roberto D. Polakiewicz, Johannes L. Roesel, Titus J. Boggon, Fadlo R. Khuri, D. Gary Gilliland, Lewis C. Cantley, Jonathan Kaufman, and Jing Chen (17 November 2009) Sci. Signal.2 (97), ra73.
[DOI: 10.1126/scisignal.2000431] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
EDITORS' CHOICE
Paula A. Kiberstis (22 September 2009) Sci. Signal.2 (89), ec312.
[DOI: 10.1126/scisignal.289ec312] |Abstract »
EDITORIAL GUIDES
Elizabeth M. Adler (6 January 2009) Sci. Signal.2 (52), eg1.
[DOI: 10.1126/scisignal.252eg1] |Abstract »|Full Text »|PDF »
EDITORS' CHOICE
Nancy R. Gough (18 March 2008) Sci. Signal.1 (11), ec97.
[DOI: 10.1126/stke.111ec97] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Mitochondrial Mutations Contribute to HIF1{alpha} Accumulation via Increased Reactive Oxygen Species and Up-regulated Pyruvate Dehydrogenease Kinase 2 in Head and Neck Squamous Cell Carcinoma.
W. Sun, S. Zhou, S. S. Chang, T. McFate, A. Verma, and J. A. Califano (2009)
Clin. Cancer Res.
15, 476-484
|Abstract »|Full Text »|PDF »
Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer.
M. A. Kiebish, X. Han, H. Cheng, J. H. Chuang, and T. N. Seyfried (2008)
J. Lipid Res.
49, 2545-2556
|Abstract »|Full Text »|PDF »
Dietary Energy Restriction Modulates the Activity of AMP-Activated Protein Kinase, Akt, and Mammalian Target of Rapamycin in Mammary Carcinomas, Mammary Gland, and Liver.
